

Ref No.: ZLL/CS/BM/BSE-NSE

Date : 20.05.2025

BSE Limited, Compliance Department, P. J. Towers, Dalal Street, Mumbai – 400 001 (Scrip Code - 541400)	National Stock Exchange of India Limited, Listing Compliance Department, Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
--	---

Dear Sir,

Sub : **Outcome of Board Meeting held on 20.05.2025**

Ref : **Intimation of Board Meeting dt. 14.05.2025**

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today has inter-alia considered and approved:

- 1) The Audited Financial Statements (Standalone and Consolidated) of the Company for the year ended 31st March, 2025.

The Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended 31st March, 2025 (prepared pursuant to SEBI (LODR) Regulations, 2015).

Walker Chandiook & Co LLP, Chartered Accountants, the Statutory Auditors of the Company have issued auditor's report with an unmodified opinion on the financial results for the year ended 31.03.2025 which is enclosed herewith.

- 2) Appointment of Deloitte Haskins & Sells LLP (**Firm Registration No.: 117366WW-100018**) as the Statutory Auditors of the Company for a first term of five years commencing from F.Y 2025-26 till F.Y 2029-30, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting.
- 3) Appointment of BNP & Associates (**Firm Registration No.: P2014MH037400**) as the Secretarial Auditors of the Company for a first term of five years commencing from F.Y 2025-26 till F.Y 2029-30, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CI R/2023/123 dated July 13, 2023 are enclosed as Annexure I & Annexure II.

Kindly take the intimation on record.

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172



Zeal & Innovation in Medicine

The Board Meeting commenced at 3:00 p.m. and concluded at 7:30 p.m.

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

PIYUSH
SIDDHESHWAR
NIKHADE

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Digitally signed by PIYUSH SIDDHESHWAR NIKHADE
DN: c=IN, postalCode=400121, o=MAHARASHTRA, st=MH, email=SIDDHESHWAR.NIKHADE@ZIMLAB.COM, serial=3226,
serialNumber=3226, uri=urn:ietf:params:spki:uri=mailto:SIDDHESHWAR.NIKHADE@ZIMLAB.COM, cn=PIYUSH SIDDHESHWAR NIKHADE
Date: 2025.01.20 19:47:15 +05'30'
Adobe Acrobat version: 11.0.17

Encl: as above

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.7118.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960

Walker Chandiook & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India

T +91 22 6626 2699
F +91 22 6626 2601

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of ZIM Laboratories Limited

Opinion

1. We have audited the accompanying consolidated annual financial results ('the Statement') of **ZIM Laboratories Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries, included in the Statement) for the year ended **31 March 2025**, attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditors on separate/consolidated audited financial statements of the subsidiaries, as referred to in paragraph 12 below, the Statement:
 - (i) includes the annual financial results of the entities listed in Annexure 1;
 - (ii) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations; and
 - (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the consolidated net profit after tax and other comprehensive income and other financial information of the Group, for the year ended 31 March 2025.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in *the Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the consolidated financial results under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, together with the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph 12 of the Other Matter section below, is sufficient and appropriate to provide a basis for our opinion.

ZIM Laboratories Limited

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Responsibilities of Management and Those Charged with Governance for the Statement

4. The Statement, which is the responsibility of the Holding Company's management and has been approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the consolidated net profit and other comprehensive income, and other financial information of the Group, in accordance with the Ind AS prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Holding Company's Board of Directors is also responsible for ensuring accuracy of records including financial information considered necessary for the preparation of the Statement. Further, in terms of the provisions of the Act, the respective Board of Directors of the companies included in the Group, covered under the Act, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Group, and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively, for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results, that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial results have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.
5. In preparing the Statement, the respective Board of Directors of the companies included in the Group, are responsible for assessing the ability of the Group, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
6. Those respective Boards of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group.

Auditor's Responsibilities for the Audit of the Statement

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act will always detect a material misstatement, when it exists. Misstatements can arise from fraud or error, and are considered material if, individually, or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

ZIM Laboratories Limited

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

8. As part of an audit in accordance with the Standards on Auditing specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;
 - Conclude on the appropriateness of Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group, to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern;
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation; and
 - Obtain sufficient appropriate audit evidence regarding the financial results/ financial statements of the entities within the Group, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement, of which we are the independent auditors. For the other entities included in the Statement, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
9. We communicate with those charged with governance of the Holding Company and such other entities included in the Statement, of which we are the independent auditors, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

ZIM Laboratories Limited

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

11. We also performed procedures in accordance with circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matters

12. We did not audit the standalone/consolidated annual financial statements of seven subsidiaries included in the Statement whose standalone/consolidated financial statements (before eliminating inter-company balances/transactions) reflects total assets of ₹ 2,861.76 lakhs as at 31 March 2025, total revenues of ₹ 3,916.61 lakhs, total net profit after tax of ₹ 42.09 lakhs total comprehensive income of ₹ 93.24 lakhs and net cash outflows of ₹ 796.92 lakhs for the year ended on that date, as considered in the Statement. These standalone/consolidated financial statements have been audited by other auditors whose audit reports have been furnished to us by the management, and our opinion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the audit reports of such other auditors and the procedures performed by us as stated in paragraph 11 above.

Further, of these subsidiaries, four subsidiaries are located outside India, whose standalone/consolidated financial statements have been prepared in accordance with accounting principles generally accepted in their respective countries, and which have been audited by other auditors under International Standards on Auditing applicable in their respective countries. The Holding Company's management has converted the financial statements of such subsidiaries from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Holding Company's management. Our opinion, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based on the audit report of other auditors and the conversion adjustments prepared by the management of the Holding Company and audited by us.

Our opinion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors/ Independent firm of Chartered Accountants.

13. The Statement includes the consolidated financial results for the quarter ended 31 March 2025, being the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year-to-date consolidated figures up to the third quarter of the current financial year, which were subjected to a limited review by us.

For **Walker Chandiook & Co LLP**

Chartered Accountants

Firm Registration No:001076N/N500013

KHUSHROO Digitally signed by
B PANTHAKY KHUSHROO B PANTHAKY
Date: 2025.05.20 16:57:56
+05'30'

Khushroo B. Panthaky

Partner

Membership No:042423

UDIN:25042423BMNRBU5663

Place: Nagpur

Date: 20 May 2025

ZIM Laboratories Limited
Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Annexure 1

List of entities included in the Statement

Subsidiary companies

1. ZIM Laboratories FZE (UAE)
2. ZIM Health Technologies Limited (India)
3. SIA ZIM Laboratories Limited (Latvia)
4. ZIM Thinorals Private Limited (India)
5. ZIMTAS PTY Limited (w.e.f. 5 March 2024) (Australia)
6. ZIM Laboratories Middle East DMCC (w.e.f. 28 September 2023) (UAE)
7. ZIM Scientific Office L.L.C (w.e.f. 15 November 2024) (UAE)

KHUSHROO
B PANTHAKY

Digitally signed by
KHUSHROO B PANTHAKY
Date: 2025.05.20 16:58:39
+05'30'



ZIM Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India
CIN:L99999MH1984PLC032172, Website: www.zimlab.in

A. STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31 MARCH 2025

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Year ended	
		31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024
		(Unaudited) Refer Note 3	(Unaudited)	(Unaudited) Refer Note 3	(Audited)	(Audited)
1	Income					
	a) Revenue from operations	10,873.30	9,633.03	11,786.28	37,903.10	36,742.44
	b) Other income	170.98	175.46	153.47	578.41	518.39
	Total income	11,044.28	9,808.49	11,939.75	38,481.51	37,260.83
2	Expenses					
	a) Cost of materials consumed	4,860.09	3,987.54	5,348.58	15,500.40	17,769.83
	b) Purchases of stock-in-trade	329.59	248.65	211.83	1,157.82	779.61
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(364.14)	(110.78)	58.65	126.65	(1,405.32)
	d) Employee benefits	1,632.46	1,447.47	1,471.19	6,075.98	5,334.27
	e) Finance costs	290.92	273.30	227.71	1,138.82	692.44
	f) Depreciation and amortisation	528.90	488.07	390.53	2,011.34	1,595.18
	g) Other expenses	2,955.62	2,903.87	3,131.30	10,669.56	10,130.58
	Total expenses	10,233.44	9,238.12	10,839.79	36,680.57	34,896.59
3	Profit before tax (1-2)	810.84	570.37	1,099.96	1,800.94	2,364.24
4	Tax expense					
	Current Tax	340.33	74.76	(128.73)	467.41	94.15
	Deferred Tax	(17.94)	95.53	420.13	117.03	545.46
	Total tax expense	322.39	170.29	291.40	584.44	639.61
5	Net Profit after tax (3-4)	488.45	400.08	808.56	1,216.50	1,724.63
6	Other comprehensive income - profit/(loss)					
	a) Items that will not be reclassified to profit or loss	(35.54)	(13.47)	(5.03)	(75.95)	(53.88)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	10.35	3.92	1.47	22.11	15.69
	c) Items that may be reclassified to profit or loss	(14.05)	37.80	(3.50)	51.09	13.29
	d) Tax (expense)/credit on the items that will be reclassified to profit or loss	-	-	-	-	-
	Other comprehensive income (net of tax) - profit/(loss)	(39.24)	28.25	(7.06)	(2.75)	(24.90)
7	Total comprehensive income (5+6)	449.21	428.33	801.50	1,213.75	1,699.73
8	Net Profit after tax attributable to					
	Owners	488.47	400.08	808.57	1,216.52	1,724.64
	Non-controlling interest	(0.02)	-	(0.01)	(0.02)	(0.01)
9	Other comprehensive Income attributable to					
	Owners	(39.24)	28.25	(7.06)	(2.75)	(24.90)
	Non-controlling interest	-	-	-	-	-
10	Total Comprehensive Income attributable to					
	Owners	449.23	428.33	801.51	1,213.77	1,699.74
	Non-controlling interest	(0.02)	-	(0.01)	(0.02)	(0.01)
11	Paid-up equity share capital (face value of Rs. 10/- each)	4,872.58	4,872.58	4,872.58	4,872.58	4,872.58
12	Other equity (revaluation reserve : Rs. Nil)				20,351.17	19,002.00
13	Earnings per share (face value of Rs. 10/- each) (not annualised for the quarters) (Rs.)					
	Basic	1.01	0.82	1.66	2.50	3.54
	Diluted	1.01	0.82	1.66	2.50	3.54



B. Consolidated Balance Sheet

	As at 31.03.2025 Rs. in lakhs (Audited)	As at 31.03.2024 Rs. in lakhs (Audited)
ASSETS		
Non-current assets		
Property, Plant and Equipment	15,834.39	15,693.35
Capital work-in-progress	4,405.44	2,351.60
Goodwill on consolidation	16.94	16.94
Other intangible assets	576.33	372.34
Intangible assets under development	2,641.05	1,876.68
Financial Assets		
Investments	5.00	5.15
Other financial assets	103.27	78.55
Income tax assets (net)	103.82	386.78
Other non-current assets	385.36	1,135.99
	24,071.60	21,917.38
Current assets		
Inventories	8,647.00	8,126.29
Financial Assets		
Trade receivables	10,692.03	10,016.54
Cash and cash equivalents	194.66	960.02
Bank balances other than cash and cash equivalents	54.59	86.38
Other financial assets	30.67	31.85
Other current assets	3,511.79	3,543.77
	23,130.74	22,764.85
TOTAL ASSETS	47,202.34	44,682.23
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4,872.58	4,872.58
Other equity	20,351.17	19,002.00
Equity attributable to equity holders of the parent	25,223.75	23,874.58
Non controlling interest	0.05	0.03
Total equity	25,223.80	23,874.61
Liabilities		
Non-current liabilities		
Financial Liabilities		
Borrowings	4,030.10	3,560.06
Lease Liabilities	206.97	294.95
Deferred tax liabilities (net)	1,105.01	1,010.09
	5,342.08	4,865.10
Current liabilities		
Financial Liabilities		
Borrowings	7,186.45	7,075.20
Lease Liabilities	356.43	247.18
Trade payables		
-total outstanding due of micro enterprises and small enterprises	668.46	466.37
-total outstanding due of creditors other than micro enterprises and small enterprises	6,282.12	5,771.72
Other financial liabilities	1,170.36	1,077.72
Other current liabilities	612.70	1,224.65
Provisions	67.90	79.68
Current Tax Liabilities (net)	292.04	-
	16,636.46	15,942.52
TOTAL LIABILITIES	21,978.54	20,807.62
TOTAL EQUITY AND LIABILITIES	47,202.34	44,682.23



C. Consolidated Statement of Cash Flow

	Year ended 31 March 2025	Year ended 31 March 2024
	Rs. in lakhs	Rs. in lakhs
	(Audited)	(Audited)
Cash flow from operating activities		
Profit before tax	1,800.94	2,364.24
Depreciation and amortisation expenses	2,011.34	1,595.18
Government Incentive	(10.24)	(9.26)
Interest on lease deposits	(7.14)	(4.55)
(Gain) on sale of property, plant and equipment (net)	(33.51)	(46.97)
Property, plant and equipment written off	13.71	-
Unrealized foreign exchange (gain)	(29.99)	(113.98)
Provision for employee benefits	(110.05)	(0.04)
Dividend income on investments	(0.75)	(0.60)
Interest income	(5.11)	(4.29)
Share based payments to employees	135.40	-
Bad debts written off	212.71	110.07
Loss allowance - trade receivables	(71.97)	(17.47)
Finance costs	1,138.82	692.44
Operating profit before working capital changes	5,044.16	4,564.77
Movement in working capital :		
(Increase) in inventories	373.35	790.81
(Increase) in trade and other receivables	(520.71)	(2,755.67)
(Increase)/decrease in trade and other receivables	(888.93)	(713.65)
Net Cash generated from operations	4,007.87	1,886.26
Direct taxes paid (net of refunds)	107.59	(258.44)
Net cash from operating activities (A)	4,115.46	1,627.82
Cash flow from investing activities		
Purchases of property, plant and equipment and intangibles (Refer Note i)	(4,079.77)	(7,392.32)
Sale proceeds of property, plant and equipment and intangibles	73.20	54.81
Deposits placed with bank (having original maturity of more than three months)	(35.50)	(28.39)
Maturity of bank deposits (having original maturity of more than three months)	44.03	59.71
Interest received	4.59	4.33
Dividend received	0.75	0.60
Net cash (used in) investing activities (B)	(3,992.70)	(7,301.26)
Cash flow from financing activities		
Deemed equity contribution from shareholder (net)	-	2,140.24
Proceeds from long term borrowings	2,462.40	2,814.69
(Repayment) of long term borrowings	(1,532.02)	(1,293.25)
(Repayment) of short term borrowings (net)	(252.65)	3,215.47
(Repayment) of principal portion of lease obligations	(358.16)	(172.39)
Finance costs paid	(1,230.02)	(751.36)
Changes in unclaimed dividend bank balances	5.69	4.93
Dividends paid on equity shares (including unclaimed)	(5.69)	(4.93)
Net cash generated from/ (used in) financing activities (C)	(910.45)	5,953.40
Effects of exchange rate changes on cash and cash equivalents (D)	22.33	38.01
Net increase in cash and cash equivalents (A+B+C+D)	(765.36)	317.97
Opening cash and cash equivalents	960.02	642.05
Closing cash and cash equivalents	194.66	960.02
Components of cash and cash equivalents		
Cash on hand	4.42	11.76
Balances with banks in:		
- Current accounts	190.24	948.26
Total Cash and cash equivalents	194.66	960.02

Note (i) Includes capital work-in-progress, capital advance, payables for property, plant and equipment, intangibles assets and intangible assets under development.

Note (ii) The Statement of Cash Flow has been prepared under the indirect method as set out in Indian Accounting Standard (Ind AS 7) Statement of Cash flows



Notes (A to C):

- 1) The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 20 May 2025. There are no qualifications in the audit report issued for the year ended 31 March 2025.
- 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The figures for the quarter ended 31 March 2025 and 31 March 2024 represent the balance between audited figures in respect of the full financial years and those published till the third quarter of the respective financial years, which were subjected to a limited review by the statutory auditor.
- 4) The Company and its subsidiaries are principally engaged in a single business segment which is "pharmaceuticals".
- 5) Figures of previous period/year have been regrouped/rearranged wherever necessary. The impact of the same is not material to the users of financial statement.

Place: Nagpur
Date: 20 May 2025

**ANWAR
SIRAJ DAUD**

Digitally signed by ANWAR SIRAJ DAUD
DN: cn=ANWAR SIRAJ DAUD, o=ANWAR SIRAJ DAUD,
ou=ANWAR SIRAJ DAUD, email=ANWAR.SIRAJ.DAUD@ANWAR.SIRAJ.DAUD.COM,
c=IN

Anwar S. Daud
Managing Director



Walker Chandiook & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India

T +91 22 6626 2699
F +91 22 6626 2601

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of ZIM Laboratories Limited

Opinion

1. We have audited the accompanying standalone annual financial results ('the Statement') of **ZIM Laboratories Limited** ('the Company') for the year ended **31 March 2025**, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations, and
 - (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company for the year ended 31 March 2025.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

ZIM Laboratories Limited
Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Responsibilities of Management and Those Charged with Governance for the Statement

4. This Statement has been prepared on the basis of the standalone annual financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
5. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing, specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls;

ZIM Laboratories Limited
Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;
 - Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11. The Statement includes the financial results for the quarter ended 31 March 2025, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us.

For **Walker Chandiook & Co LLP**
Chartered Accountants
Firm Registration No:001076N/N500013

KHUSHROO Digitally signed by
KHUSHROO B PANTHAKY
B PANTHAKY Date: 2025.05.20
16:59:10 +05'30'

Khushroo B. Panthaky
Partner
Membership No:042423

UDIN:25042423BMNRBT2439

Place: Nagpur
Date: 20 May 2025



ZIM Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India
CIN:L99999MH1984PLC032172, Website: www.zimlab.in

A. STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31 MARCH 2025

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Year ended	
		31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024
		(Unaudited) Refer Note 3	(Unaudited)	(Unaudited) Refer Note 3	(Audited)	(Audited)
1	Income					
	a) Revenue from operations	10,851.51	9,539.50	11,738.72	37,563.55	36,547.32
	b) Other income	155.44	176.47	153.12	562.09	469.10
	Total income	11,006.95	9,715.97	11,891.84	38,125.64	37,016.42
2	Expenses					
	a) Cost of materials consumed	4,860.09	3,987.54	5,348.58	15,500.40	17,769.83
	b) Purchases of stock-in-trade	329.59	248.65	211.83	1,157.82	779.61
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(364.14)	(110.78)	58.65	126.65	(1,405.32)
	d) Employee benefits	1,532.91	1,315.90	1,411.97	5,640.62	5,081.03
	e) Finance costs	290.92	273.30	227.71	1,138.58	692.44
	f) Depreciation and amortisation	523.37	476.83	387.48	1,989.14	1,482.93
	g) Other expenses	2,969.36	2,921.75	3,165.31	10,811.22	10,311.93
	Total expenses	10,142.10	9,113.19	10,811.53	36,364.43	34,712.45
3	Profit before tax (1-2)	864.85	602.78	1,080.31	1,761.21	2,303.97
4	Tax expense					
	Current Tax	334.20	65.87	(128.85)	444.69	82.96
	Deferred Tax	(11.43)	102.06	420.13	142.12	545.46
	Total tax expense	322.77	167.93	291.28	586.81	628.42
5	Profit after tax (3-4)	542.08	434.85	789.03	1,174.40	1,675.55
6	Other comprehensive income - profit/(loss)					
	a) Items that will not be reclassified to profit or loss	(35.54)	(13.47)	(5.03)	(75.95)	(53.88)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	10.35	3.92	1.47	22.11	15.69
	Other comprehensive income (net of tax) - profit/(loss)	(25.19)	(9.55)	(3.56)	(53.84)	(38.19)
7	Total comprehensive income (5+6)	516.89	425.30	785.47	1,120.56	1,637.36
8	Paid-up equity share capital (face value of Rs. 10/- each)	4,872.58	4,872.58	4,872.58	4,872.58	4,872.58
9	Other equity (revaluation reserve : Rs. Nil)				19,578.80	18,322.84
10	Earnings per share (face value of Rs. 10/- each) (not annualised for quarters) (Rs.)					
	Basic	1.11	0.89	1.62	2.41	3.44
	Diluted	1.11	0.89	1.62	2.41	3.44



B. Standalone Balance Sheet

	As at 31.03.2025 Rs. in lakhs (Audited)	As at 31.03.2024 Rs. in lakhs (Audited)
ASSETS		
Non-current assets		
Property, Plant and Equipment	15,828.14	15,691.89
Capital work-in-progress	4,405.44	2,351.60
Intangible assets	531.39	357.43
Intangible assets under development	2,161.15	1,673.11
Financial Assets		
Investment in subsidiaries	1,298.90	817.81
Other Investments	5.00	5.15
Other financial assets	102.18	78.30
Income tax assets (net)	86.25	367.43
Other non-current assets	385.36	1,135.99
	24,803.81	22,478.71
Current assets		
Inventories	8,647.00	8,126.29
Financial Assets		
Trade receivables	9,368.06	10,009.25
Cash and cash equivalents	36.36	17.35
Bank balances other than cash and cash equivalents	45.59	57.99
Other financial assets	30.67	31.85
Other current assets	3,507.03	3,528.59
	21,634.71	21,771.32
TOTAL ASSETS	46,438.52	44,250.03
EQUITY AND LIABILITIES		
Tax expense/(credit)		
Equity share capital	4,872.58	4,872.58
Other equity	19,578.80	18,322.84
	24,451.38	23,195.42
Liabilities		
Non-current liabilities		
Financial Liabilities		
Borrowings	4,030.10	3,560.06
Lease Liabilities	206.97	294.95
Deferred tax liabilities (net)	1,130.10	1,010.09
	5,367.17	4,865.10
Current liabilities		
Financial Liabilities		
Borrowings	7,186.45	7,075.20
Lease Liabilities	356.43	247.18
Trade payables		
-total outstanding due of micro enterprises and small enterprises	668.46	466.37
-total outstanding due of creditors other than micro enterprises and small enterprises	6,518.14	5,800.09
Other financial liabilities	1,011.97	1,063.51
Other current liabilities	518.58	1,457.48
Provisions	67.90	79.68
Current Tax Liabilities (net)	292.04	-
	16,619.97	16,189.51
TOTAL LIABILITIES	21,987.14	21,054.61
TOTAL EQUITY AND LIABILITIES	46,438.52	44,250.03



C. Standalone Statement of Cash Flow

	Year ended 31.03.2025 Rs. in lakhs (Audited)	Year ended 31.03.2024 Rs. in lakhs (Audited)
Cash flow from operating activities		
Profit before tax	1,761.21	2,303.97
Depreciation and amortisation expenses	1,989.14	1,482.93
Government Incentive	(10.24)	(9.26)
Interest on lease deposits	(7.14)	(4.55)
(Gain) on sale of property, plant and equipment (net)	(12.12)	(0.19)
Unrealized foreign exchange (gain)	(30.03)	(113.98)
Provision for employee benefits	(110.05)	(0.04)
Dividend income on investments	(0.75)	(0.60)
Interest income	(4.55)	(3.18)
Share based payments to employees	39.40	-
Bad debts written off	212.71	110.07
Loss allowance - trade receivables	(71.97)	(17.47)
Finance costs	1,138.58	692.44
Operating profit before working capital changes	4,907.90	4,440.14
Movement in working capital :		
Increase in trade and other payables and provisions	81.11	1,117.00
(Increase) in inventories	(520.71)	(2,755.67)
(Increase)/decrease in trade and other receivables	463.37	(1,397.44)
Net Cash generated from operations	4,931.67	1,404.03
Direct taxes paid (net of refunds)	128.53	(256.83)
Net cash from operating activities (A)	5,060.20	1,147.20
Cash flow from investing activities		
Purchases of property, plant and equipment and intangibles (Refer Note i)	(3,791.66)	(7,259.31)
Sale proceeds of property, plant and equipment and intangible assets	51.81	6.92
Tax expense/(credit)	(385.09)	(5.37)
Deposits placed with bank (having original maturity of more than three months)	(26.50)	-
Maturity of bank deposits (having original maturity of more than three months)	15.64	59.71
Interest received	4.03	3.22
Dividend received	0.75	0.60
Net cash (used in) investing activities (B)	(4,131.02)	(7,194.23)
Cash flow from financing activities		
Deemed equity contribution from shareholder(net)	-	2,140.24
Proceeds from long term borrowings	2,462.40	2,814.69
(Repayment) of long term borrowings	(1,532.02)	(1,293.25)
Proceeds/(Repayment) of short term borrowings (net)	(252.65)	3,215.47
(Repayment) of principal portion of lease obligations	(358.16)	(172.39)
Finance costs paid	(1,229.78)	(751.36)
Changes in unclaimed dividend bank balances	5.69	4.93
Dividends paid on equity shares (unclaimed)	(5.69)	(4.93)
Net cash generated from financing activities (C)	(910.21)	5,953.40
Effects of exchange rate changes on cash and cash equivalents (D)	0.04	-
Net (decrease)/increase in cash and cash equivalents (A+B+C+D)	19.01	(93.63)
Opening cash and cash equivalents	17.35	110.98
Closing cash and cash equivalents	36.36	17.35
Components of cash and cash equivalents		
Cash on hand	4.42	11.75
Balances with banks in:		
- Current accounts	31.94	5.60
Total Cash and cash equivalents	36.36	17.35



Note (i) Includes capital work-in-progress, capital advance, payables for property, plant and equipment, intangibles assets and intangible assets under development.

Note (ii) The Standalone Statement of Cash Flow has been prepared under the indirect method as set out in Indian Accounting Standard (Ind AS 7) Statement of Cash flows

Annexure- I

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July, 2023

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Deloitte Haskins & Sells LLP as Statutory Auditor of the Company.
2.	Date of appointment/ re-appointment/cessation and Term of appointment/ re-appointment	The appointment will be effective from the conclusion of the 41 st Annual General Meeting (AGM) till the conclusion of 46 th AGM i.e, for one term of five years subject to the approval of the shareholders in the ensuing 41 st Annual General Meeting.
3.	Brief profile (in case of appointment)	Deloitte Haskins & Sells LLP is a Firm of Chartered Accountants in Practice registered with The Institute of Chartered Accountants of India, New Delhi, bearing Firm registration no. 117366W/W-100018. The firm is Peer reviewed and engaged in rendering Audit & Assurance Services, Advisory and allied Services.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

ZIM LABORATORIES LIMITED

Annexure- II

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July, 2023

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Secretarial Auditor pursuant to Section 204 of the Companies Act, 2013 and Regulation 24A of the SEBI (LODR) Regulations, 2015
2.	Date of appointment/ re-appointment/cessation and Term of appointment/ re-appointment	The appointment will be effective from the conclusion of the 41 st Annual General Meeting (AGM) till the conclusion of 46 th AGM i.e, for one term of five years subject to the approval of the shareholders in the ensuing 41 st Annual General Meeting.
3.	Brief profile (in case of appointment)	M/s BNP & Associates is a Firm of Company Secretaries in Practice registered with The Institute of Company Secretaries of India, New Delhi, bearing Firm registration no. P2014MH037400. The firm is Peer reviewed and engaged in rendering Compliance Audit & Assurance Services, Advisory and allied Services.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

ZIM LABORATORIES LIMITED